Trial reportFrontiers in medicine2026
Effect of oliceridine pretreatment on etomidate-induced myoclonus: a prospective, randomized, double-blind, controlled study.
Trial report in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of Oliceridine Pretreatment on Etomidate-Induced Myoclonus: A Proof-of-Concept Randomized Trial.Drug design, development and therapy · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Etomidate often induces adverse effects such as myoclonus during anesthesia induction, thereby increasing perioperative risks for patients to some extent. Oliceridine is a novel opioid with fewer opioid-related adverse reactions. This study aims to investigate the effect of oliceridine pretreatment on etomidate-induced myoclonus. Patients and methods: This study is a prospective, randomized, double-blind, controlled study. Patients scheduled for elective surgery under general anesthesia were selected and randomly divided into the oliceridine group (Group O) and the normal saline group (Group C), with 45 patients in each group. Two minutes before etomidate administration, Group O and Group C were given 0.02 mg/kg oliceridine and an equal volume of normal saline, respectively. Primary outcome measure: the incidence of etomidate-induced myoclonus. Secondary outcome measures: the severity of etomidate-induced myoclonus, as well as adverse reactions and hemodynamic changes occurring during the observation period. Results: The incidence of myoclonus in Group O was significantly lower than that in Group C (13.3% vs. 51.1%, RR = 0.45, 95% confidence interval [95%CI] = 0.310-0.667, Conclusion: Pretreatment with oliceridine can significantly reduce the incidence of etomidate-induced myoclonus. Therefore, oliceridine can be used as a new pretreatment strategy when etomidate is employed for anesthetic induction. Clinical trial registration: https://www.chictr.org.cn/searchproj.html, identifier ChiCTR2500108944.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.